Effect of dapagliflozin on HbA1c and weight after its addition to various combinations of other diabetes medications: Association of British Clinical Diabetologist (ABCD) nationwide dapagliflozin audit

M Yadagiri1, P Sen Gupta1, T Pang2, L Balmuri2, T Robinson3, S Bain4, I W. Gallen5, K A Adamson6, and R E J Ryder1 on behalf of ABCD dapagliflozin audit contributors

1 Sandwell and West Birmingham NHS Trust, Birmingham, UK, 2 Dudley Group Hospitals NHS Trust, Dudley, UK, 3 Chorley and South Ribble Hospital, Chorley, UK, 4 Royal United Hospital, Bath, UK, 5 Abertawe Bro Morganwng NHS Trust, Swansea, UK, 6 Royal Berkshire NHS Trust, Reading, UK, 7 West Lothian NHS Trust, Edinburgh, UK

**BACKGROUND**

The ABCD audits new pharmacotherapies for diabetes across the UK to collect real-world data on their usage, accelerate the understanding of new agents in patients in the UK and ascertain whether experience from clinical usage matches phase 3 trial data.

**AIMS**

To evaluate the effect on HbA1c and weight after adding dapagliflozin to various combinations of other diabetes medications, in patients with type 2 diabetes in the UK was collected by the Association of British Clinical Diabetologists (ABCD) nationwide audit.

**METHODS**

The ABCD nationwide audit of dapagliflozin in real clinical use in the UK, was launched in October 2014. Anonymised data of patients treated with dapagliflozin in the UK was collected by an online password protected questionnaire:

- Patient demographics
- HbA1c, weight, BMI, Systolic BP
- Diabetes medications
- Adverse events

ABCD members, clinicians in both primary care and secondary care were emailed to invite them to submit clinical data on their patients treated with dapagliflozin.

**BASELINE CHARACTERISTICS**

Patients were categorized into 6 groups according to their other diabetes therapies, dapagliflozin was added to: group 1 (metformin, n=148), group 2 (metformin and sulphonylurea, n=113), group 3 (metformin and dipeptidyl peptidase-4 inhibitor (DPP4-i), n=68), group 4 (pioglitazone with or without any other diabetes medications, n=46), group 5 (glucagon-like peptide-1 receptor agonist with or without any other diabetes medications, n=248) and group 6 (insulin with or without any other diabetes medications, n=342).

**RESULTS**

Weight fell by (-2.8±0.5) kg from 101.2±26.1 kg to 98.3±20.9 kg, p<0.001) in group 1, (-3.1±0.4) kg from 99.6±24.2 kg to 96.5±24.2 kg, p<0.001 in group 2, (-3.8±0.6) kg to 98.3±22.7 kg to 90.9±22.7 kg, p<0.001 in group 3, (-2.9±0.6) kg from 104.7±25.9 kg to 101.8±25.9 kg, p<0.001 in group 4, (-3.6±1.3) kg from 108.8±24.3 kg to 105.5±24.3 kg, p<0.001 in group 5, (-2.0±0.2) kg from 104.7±0.9 kg to 102.6±0.9 kg, p<0.001 in group 6.

**CONCLUSION**

The different treatment groups all had similar poor glycaemic control (HbA1c>9%) but they varied with regard to duration of diabetes (longest duration were insulin and GLP-1 treated patients groups), BMI (heaviest GLP-1 and pioglitazone treated patients), age (youngest metformin only and pioglitazone treated patients) and sex distribution (pioglitazone treated predominantly male, DPP4i predominantly female).

Despite these differences dapagliflozin reduced both HbA1c and weight by clinically and statistically significant amounts in all the groups in this wide range of real world UK patients with type 2 diabetes on a variety of diabetes medications. Whilst the biggest impact was on those on DPP4i group and least for those on insulin, these differences were not statistically significant.

**ACKNOWLEDGEMENT**

We thank all the nationwide contributors for submitting data of patients on dapagliflozin. The ABCD nationwide dapagliflozin audit is supported by an unrestricted grant from AstraZeneca. The audit was independently initiated and performed by ABCD and the authors remained independent in the analysis and the writing of this report.